Address: Đorđa Stanojevića 11d/37 (Belville)
11070 Beograd
Srbija
Tel: + 381 11 63 00 685
Web: http://inovia.rs/
The Inovative Drug Manufacturers’ Fund – INOVIA is the representative body of the innovative pharmaceutical industry in Republic of Serbia and was established in February 2007. Its members are sixteen leading R&D multinational companies – Abbott, Alcon, Astra Zeneca, Bayer Schering Pharma, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen Cilag – a division of Johnson&Johnson, Les Laboratories Servier, Lundbeck Export A/S, Merck d.o.o., Merck Sharp & Dohme Idea Inc., Novartis, Novo Nordisk, Pfizer, Roche and Sanofi-Aventis.
INOVIA’s primary mission is to promote the technological and economic development of the pharmaceutical industry in Republic of Serbia and to assist in bringing to market medicinal products which improve human health worldwide.
INOVIA objectives are: Promotion of and education around lifestyle, habits and activities critical for achieving better health and quality of people’s lives; establishment of transparent, systematic, constructive and partnership like dialogue with leading governmental and non-governmental organisations in Serbia with the objective to identify and implement best-practice regulations, strategy and solutions, necessary for maximization of public health quality in Serbia and full protection of intelectual property (IPR) of proprietary drugs in the Serbian market.
INOVIA aims to establish transparent, systematic, constructive and partnership like dialogue with leading governmental and NGO institutions in Serbia with the objective to identify and implement best-practice regulations.
One of INOVIA’s initiatives was the adoption of a Code on the Promotion of Prescription Only Medicines to, and Interactions with Healthcare Professionals, which has been signed by all INOVIA members. The detailed provisions in the Code are to ensure that pharmaceutical companies operate in a responsible, ethical and professional manner. The Code covers the industry’s activities only.
drugs
Bojan Trkulja, managing director of INOVIA, Serbia’s innovative drug manufacturers association, underlines the importance of cooperation not only between his members but also between all the key stakeholders of the…
INOVIA was founded in 2007, which is quite recent for a multinational pharmaceutical association. Why was the time right at that point to start INOVIA? There was an informal association…
How does Janssen view the Serbian market today, and how has company built up its presence here in the country? Previously we were working through distribution channels and in 2003…
Novo Nordisk has a long history in Serbia compared to many of the other multinational companies present in the country today. The separate entity Novo Nordisk d.o.o was founded in…
INOVIA was founded in 2007, which is quite recent for a multinational pharmaceutical association. Why was the time right at that point to start INOVIA? There was an informal association…
Throughout its history, Zdravlje Actavis has grown into one of the 3 companies that really define Serbian pharma. What have been the main factors that got Actavis into this leading…
From a Zemun-based Belgrade drug manufacturer, Galenika has grown into a leader in Serbia with an increasing footprint worldwide. How would you describe the company today? In its 65 year-long…
See our Cookie Privacy Policy Here
